Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2016 is made possible in part by the generous support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Sort by:
  • Browse by:
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 25 of 54
Oral Abstract Session 01: Antibody Epitopes: Connecting the Dots
A Prominent Site of Antibody Vulnerability on HIV Env Incorporates the CCR5 Coreceptor Site and Its Camouflaging Glycans
Devin Sok
International AIDS Vaccine Initiative (IAVI), United States
HIV-1 MPER-directed Broadly Neutralizing Antibodies from an Acute-infection Cohort RV217 Subject
Nicole A. Doria-Rose
Vaccine Research Center, NIAID, NIH, United States
Persistence of an HIV Broadly Neutralizing Antibody Lineage Despite Complete Neutralization Escape
Jinal N Bhiman
National Institute for Communicable Diseases of the National Health Laboratory Services, South Africa
Viral Escape from HIV Broadly Neutralizing Antibodies Is Slower and More Complex than for Early Strain-specific Neutralizing Antibodies
Colin Anthony
University of Cape Town, South Africa
The Anti-gp120 mAb CH58 Recognizes a Not-fully-processed Form of Surface-expressed Env
Jason Yolitz
NIAID, NIH, United States
Fusion Peptide of HIV-1 as a Site of Vulnerability to Neutralizing Antibody
Rui Kong
Vaccine Research Center, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 02: Crossing the Border: Mechanisms of Mucosal Transmission
Defining HIV/SIV Infection after Rectal Challenge in Rhesus Macaque Model Using Dual Reporter System
Danijela Maric
Northwestern University, United States
Broadly Neutralizing Antibodies Can Prevent HIV Infection in Foreskin Ex-vivo Explant Infection Models
Maria Lemos
Fred Hutchinson Cancer Research Center, United States
In Vivo Analysis of Fluorescently Tagged HIV-specific and Non-specific Antibodies in Non-human Primates
Ann M. Carias
Northwestern University, United States
HIV Susceptibility in CD4+ T Cells Derived from the Inner Versus Outer Foreskin
Ronald Galiwango
University of Toronto, Canada
Intestinal Dendritic Cells and Macrophages Differentially Affect HIV-1 Transmission Across the Intestinal Mucosa
Mariangela Cavarelli
CEA, France
Levels of Immune Activation in Cervical Cells, Rectal Cells and PBMCs Isolated from a Kenyan Women Cohort at Low-risk of HIV Acquisition
Catia Perciani
University of Toronto, Canada
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 03: PrEP Problems: Real and Imagined
The Effect of Oral Pre-exposure Prophylaxis on the Progression of HIV-1 Seroconversion
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
Infant Exposure to Tenofovir and Emtricitabine through Breast Milk when Used as Pre-exposure Prophylaxis by HIV-uninfected Lactating Women
Kenneth Mugwanya
University of Washington, United States
HIV-1 Resistance Outcomes in Seroconverters from the MTN-020/ASPIRE Dapivirine Vaginal Ring Study
Urvi M. Parikh
University of Pittsburgh, United States
Evaluation of Resistance to Cabotegravir Long-acting (CAB LA) in SIVmac251-infected Macaques
Chasity Andrews
Aaron Diamond AIDS Research Center, United States
The Potential for Condom Ideology to Cloud Clinical Judgment around Prescribing HIV Pre-exposure Prophylaxis (PrEP)
Sarah K. Calabrese
Yale School of Public Health, Yale University, United States
Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP
Howard Grossman
Cleveland Clinic, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 04: It Takes Two to Tango: Host, Hormones and Drug Levels in the Mucosa
Pharmacokinetic Analysis of Tenofovir Gel Use in Pre Versus Postmenopausal Women
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Modulation of Tenofovir (TFV) Pharmacokinetics (PK) and Antiviral Activity by Vaginal Microbiota: Implications for Topical Preexposure Prophylaxis
Ekaterina Taneva
Albert Einstein College of Medicine, United States
Hypo-osmolar Formulation of TFV Enemas Promotes Uptake and Transformation of TFV to TFV-DP in Tissues and Prevents SHIV/SIV Infection
Francois Villinger
University of Louisiana at Lafayette, United States
Use of Injectable Depot Medroxyprogesterone Acetate (DMPA) Downregulates Cervicovaginal Epithelial Barrier Genes - Similarly to Mucosal Inflammation
Irina A Zalenskaya
CONRAD, Eastern Virginia Medical School, United States
Microbiome Composition and Function Drives Wound-healing Impairment in the Female Genital Tract
Irene Xie
Public Health Agency of Canada, Canada
MPA Has Minimal Impact on HIV-1 Replication in Ectocervical Tissue Ex Vivo
Hawa Mariko
University of Pittsburgh, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 05: Risky Business
Behavioral and Biological Risk Factors among MSM in Kigali, Rwanda
Julien Nyombayire
Project San Francisco, Rwanda Zambia HIV Research Group, Rwanda
Meta-analysis and Modelling Study of Anal Sex Practices and Its Contribution to HIV Incidence among High-risk Women Across Twenty US Cities
Jocelyn Elmes
Imperial College London, United Kingdom
A Validated Risk Score to Predict HIV Acquisition in African Women: Assessing Risk Score Performance among Women who Participated in the ASPIRE Trial
Jennifer Balkus
Fred Hutchinson Cancer Research Center, United States
HIV Incidence Factors and Trends in Voluntary Counseling and Testing, Silom Community Clinic, Bangkok, Thailand, 2005-2015
Wipas Wimonsate
Thailand MOPH - U.S. CDC Collaboration, Thailand
Bacterial Vaginosis Associated Microbes Induce Altered Innate Immune Profiles
Ryan Cheu
University of Washington, United States
HIV Treatment Cascade among Transgender Women: Population-estimates from Rio de Janeiro, Brazil
Beatriz Grinsztejn
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 06: Of Mice and (Wo)men: Pharmacokinetics/Pharmacodynamics of Novel Products
Vaginal Transmission of WT or Resistant HIV-1 Was Not Inhibited by Long Acting Rilpivirine at High Plasma and Genital Concentrations in BLT Mice
Zandrea Ambrose
University of Pittsburgh School of Medicine, United States
Pharmacokinetics and Safety of Pod-intravaginal Rings Delivering VRC01-N for HIV Prophylaxis in a Macaque Model
John Moss
Oak Crest Institute of Science, United States
Pharmacokinetic Profile of Lamivudine (3TC) in Macaques and Relative Drug Exposure in Rectal and Vaginal Tissues
Ivana Massud
Centers for Disease Control and Prevention, United States
Comparison of Safety and Pharmacokinetics of Vaginal Rings Releasing Tenofovir Disoproxil Fumarate Alone and with Emtricitabine in Sheep and Humans
Kathleen Vincent
University of Texas Medical Branch, United States
Clinical Performance, Acceptability, and Optimization of Fast-dissolve Vaginal Inserts Designed for HIV-prevention: Results from Two Clinical Studies
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Assessment of the Potential for Pharmacodynamic Interaction Between Dapivirine and Levonorgestrel When Co-administered in an MPT Vaginal Ring
Jonathon Holt
International Partnership for Microbicides, United States
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 07: Through the Looking Glass: New Insights into Mucosal Biology
The Role of Gut Homing Receptor α4β7 in HIV Pathogenesis and Transmission - a Prospective Cohort Study
Aida Sivro
Center for AIDS Programme of Research in South Africa, South Africa
Immuno-PET/CT Imaging Reveals Differences in Virus and CD4+ Cell Localization in SIV Infected Rhesus Macaques Treated with an Anti-α4β7 mAb
James Arthos
NIAID, NIH, United States
Multivalent Immunoglobulin Muc5AC Complexes Enhance Antibody Potency Against HIV-1
Arangassery Rosemary Bastian
Northwestern University, United States
Semen Demons: Immunosuppressive Factors Within Semen Modulate Anti-HIV-1 Cellular Immune Responses
Kevin John Selva
University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia
Antiretroviral Therapy Contributes to Intestinal Immune Dysfunction in Healthy Macaques
Alexandra Ortiz
LPD, NIAID, NIH, United States
Initiation of c-ART During HIV Primary Infection Maintains HIV-specific Memory B Cells and Tfh Cells in the Gut Mucosa
Cyril Planchais
INSERM U955, Team 16, Vaccine Research Institute (VRI), France
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 08: A Sugar Coated Pill: Immunogenicity of Envelope
Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design
Marit van Gils
Academic Medical Center, University of Amsterdam, Netherlands
Priming a VRC01-like Antibody Response in Human Immunoglobulin Locus Transgenic Mice
Devin Sok
International AIDS Vaccine Initiative (IAVI), United States
Induction of Cross-clade Reactive, Functional Antibodies with Immunogens Targeting the V2 Region of HIV
Rebecca Powell
Icahn School of Medicine at Mount Sinai, United States
Rationally Designed Immunogens Induce Antibody Responses Targeting Polymorphic Forms of gp120 V1V2
Xunqing Jiang
New York University School of Medicine, United States
An Adenovirus 26 Vaccine Expressing Clade A Env (Ad26.EnvA) Does Not Elicit Diversionary gp41-specific Antibodies in Humans
Helen D'Couto
Beth Israel Deaconess Medical Center, United States
MVA-expressed gp140 Boosts More Durable V1/V2 and gp120 Antibody Responses than gp120 Protein in Alum
Xiaoying Shen
Duke Human Vaccine Institute, United States
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 09: HIV Antibodies: The Good, the Bad and the Ugly
Characterization of the Early Antibody Landscape in HIV-1 Infected Individuals Who Develop Poor to Elite Levels of Neutralization Breadth
S. Abigail Smith
Emory University, United States
HIV-1 Superinfection Can Lead to Potent Neutralization of the Superinfecting Virus but Is Not Sufficient to Elicit Broadly Neutralizing Antibodies
Daniel J Sheward
University of Cape Town, South Africa
Characterization of Broadly Neutralizing Antibody Responses in HIV-1 Subtype C Infected Children
Zanele Ditse
National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa
The Intrinsic Mutability of Antibody Variable Gene Is Critical for Reproducing Similar Mutation Signatures
Zizhang Sheng
Columbia University Medical Center, United States
Structure of a CH58-like V2 Antibody from Natural Infection Reveals Convergent Heavy Chain Maturation and a Novel K169 Binding Light Chain Motif
Constantinos Kurt Wibmer
National Institute for Communicable Diseases (NHLS), South Africa
Structure of a Natively-glycosylated HIV-1 Env Reveals a New Mode for VH1-2 Antibody Recognition of the CD4 Binding Site Relevant to Vaccine Design
Harry Gristick
Caltech, United States
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 10: Back to the Future: Optimizing the Cascade
Looking at the Whole Picture: The HIV Testing and Care Continuum among Community-recruited MSM, IDU, and Heterosexuals in Washington, DC, 2007-2015
Rudy Patrick
George Washington University Milken Institute School of Public Health, United States
High Uptake of Antiretroviral Treatment among Female Sex Workers in Kigali, Rwanda
Etienne Karita
Project San Francisco, Rwanda
Acceptability of a New Smartphone-based HIV and Syphilis Test to Screen Sexual Partners among High Risk MSM and Transgender Women
Iván Balán
New York State Psychiatric Institute and Columbia University, United States
Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078
Kate M. Mitchell
Imperial College London, United Kingdom
Detectable Viral Loads among Those Who Self-report Being Undetectable in the RADAR Cohort of Young MSM - Implications for Treatment as Prevention
Brian Mustanski
Northwestern University, United States
Using Peer Educators to Scale-up HIV Oral Self-testing among Female Sex Workers: An Implementation Science Approach from Kenya
Kipruto Chesang
U.S. Centers for Disease Control and Prevention, Kenya, Kenya
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 11: Testing Vaccine Concepts: Where the Rubber Hits the Road
First-in-human Clinical Trial Evaluating Mosaic HIV-1 Immunogens
Lindsey R Baden
Brigham and Women's Hospital/Harvard Medical School, United States
Optimization of a Pediatric Vaccine to Prevent Breast Milk Transmission of HIV-1
Bonnie Phillips
University of North Carolina at Chapel Hill, United States
DNA and Protein Co-delivery Vaccines Using TLR-4-based Adjuvants Induce Potent Immune Responses Able to Delay Heterologous SIV Acquisition
Barbara K. Felber
National Cancer Institute at Frederick, United States
DNA and Protein Co-administration Elicits Higher HIV-specific nAb and Comparable CD4+ T-cell Responses as Traditional Prime/Boost Regimens (HVTN 105)
Nadine Rouphael
Emory University, United States
Protective Efficacy of Candidate Clinical HIV-1 Vaccine Regimens Against SHIV-SF162P3 Challenges in Rhesus Monkeys
Frank Wegmann
Crucell Holland B.V., a Janssen pharmaceutical company of Johnson & Johnson, Netherlands
Comparing Different Priming Strategies to Optimize HIV Vaccine Antibody Responses: Results from HVTN 096/EV04 (NCT01799954)
Giuseppe Pantaleo
Swiss Vaccine Research Institute, Switzerland
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 12: Pipelines and Platforms for Prevention
Ranpirnase Exhibits Dose-dependent Inhibition of Rectal Explant Infection with HIV-1
Ian McGowan
University of Pittsburgh, United States
Development and Proof-of-Concept Clinical Evaluation of a Freeze-dried Topical Microbicide Insert for On-demand HIV Prevention
Wei Zhang
CONRAD, Eastern Virginia Medical School, United States
Foamed Silicone Intravaginal Rings for Delivery of Macromolecular Therapeutics
Matthew A. Petersen
ProMed Pharma, United States
A Single-reservoir Microbicide Intravaginal Ring for Dual Delivery of Tenofovir and Elvitegravir
Alexander Evanoff
Northwestern University, United States
Evaluation of MK-2048 and Vicriviroc, Formulated as Single or Combination (MK-2048A) Intravaginal Rings, for Development as a Vaginal Microbicide
Charlene Dezzutti
University of Pittsburgh, United States
ECLAIR Study of Cabotegravir LA Injections: Characterization of Safety and PK During the “PK Tail” Phase
Susan Ford
PAREXEL International, United States
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 13: Do Right to Do Well: Creating a Framework for Success
Harmonization of Regulatory Framework for Control of Clinical Trials in East Africa: Progress, Challenges and Lessons Learnt
Jane Humphrey Mashingia
East African Community Secretariat, Tanzania, United Republic of
Ethics Research to Inform Sexual and Gender Minority Adolescent Participation in HIV Prevention Research
Kathryn Macapagal
Northwestern University, United States
The Journey to GPP Implementation for KAVI Institute of Clinical Research
Jane Ng'ang'a
KAVI-Institute of Clinical research, University of Nairobi, Kenya
Improving the Efficiency of African Research Ethics Committees and Standardizing Ethics Review Processes - Through an Automated Review Platform
Boitumelo Mokgatla
International AIDS Vaccine Initiative (IAVI), Botswana
Toward Innovation in HIV Prevention: Sustaining Funding in a Post-2015 Landscape
Laura Marie Lazar
AVAC: Global Advocacy for HIV Prevention, United States
From Research to Policy to Implementation: A National Plan for Couples' Voluntary HIV Counseling and Testing (CVCT) in Zambia
Susan Allen
Rwanda Zambia HIV Research Group-Emory University, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 14: Teaching the Immune System New Tricks: Vaccine-Induced Immune Responses
Ex Vivo Evaluation of Mucosal Cytokine Responses to in Vivo Vaccination with ALVAC-HIV/AIDSVAX® B/E of Non-human Primates (NHPs) and Humans
Carolina Herrera
Imperial College London, United Kingdom
Vaccine-induced Antibody that Captures but Does Not Neutralize SIVmac251 Increases the Rate of Infection after Low-dose, Repeated Rectal Challenge
Johannes S. Gach
University of California Irvine, United States
NK Cell Changes after a Late Boost with ALVAC-HIV and AIDSVAX® B/E in HIV-Uninfected Thai Adults from RV144
Michael A. Eller
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States
The Relationship between Immune Responses to Tetanus Vaccine, Hepatitis B Vaccine and a Pox-protein HIV Vaccine Regimen
Ying Huang
Fred Hutchinson Cancer Research Center, United States
Broad HIV-1 Inhibition in Vitro by Vaccine-elicited CD8+ T Cells in African Adults
Josephine Cox
International AIDS Vaccine Initiative (IAVI), United States
Antibody Signature-based Design of HIV-1 Env gp140 Expands Tier 2 Neutralizing Antibody Breadth in Guinea Pigs
Christine Bricault
Beth Israel Deaconess Medical Center, Harvard Medical School, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 15: Unique and Essential: Mucosal Environment of the Female Reproductive Tract
Differences in Genital Tract Immune Cell Populations and Innate Cervicovaginal Fluid Anti-HIV Activity among Women from Zimbabwe and the United States
Sharon L. Achilles
University of Pittsburgh, United States
Very Early Mucosal Responses to Vaginal Infection of SIV
Liang Shang
University of Minnesota, United States
Characterization of Dendritic Cells with Rapid HIV Capture Potential from the Human Female Reproductive Tract
Marta Rodriguez-Garcia
Geisel School of Medicine at Dartmouth, United States
Influence of Sex Hormones and Hormonal Contraceptives on Markers of HIV Risk in the Adolescent Female Genital Tract
Smritee Dabee
University of Cape Town, South Africa
Longitudinal Combined Immunomodulatory Effects of Hormonal Contraceptives and Cervicovaginal Infections in Women Who Did or Did Not HIV Seroconvert
Charles Morrison
FHI 360, United States
Inflammatory Cytokine Responses in the Lower Female Reproductive Tract in Response to Semen
Sinaye Ngcapu
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 16: PrEP and the Real World
PrEP Initiation and Early Adherence among Young MSM and Transgender Women in Chicago in the Enhancing PrEP in Community (EPIC) Study
Albert Liu
San Francisco Department of Public Health, United States
PrEP Adherence among East African Women with HIV-infected Partners Participating in an Open-label Study
Maria Pyra
University of Washington, United States
PrEP Implementation by Local Health Departments in US Cities and Counties: Findings from a 2015 Assessment of Local Health Departments
Dawn Smith
Centers for Disease Control and Prevention, United States
Women's Knowledge of, Interest in, and Eligibility for HIV Pre-exposure Prophylaxis at Family Planning Clinics in Northern California
Dominika Seidman
University of California San Francisco, United States
Feasibility and Uptake of HIV Self-testing among Adults Visiting Community Pharmacies in Kenya
Peter Mugo
Kemri-Wellcome Trust Research Programme, Kenya
Unplanned Discontinuations of HIV Pre-exposure Prophylaxis During Clinical Care
Douglas Krakower
Beth Israel Deaconess Medical Center, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 17: Cellular Immunity Matters!
Programming T and B Cell Homing to Mucosal Sites to Induce Protective and/or Therapeutic Vaccination Using Chemokine-adjuvanted DNA Plasmids
Yoann Aldon
Imperial College London, United Kingdom
Mucosal Administration of Particulate Antigens Improves TFH Generation, HIV-specific High-quality and Long-lasting Immunity
Thomas Vazquez
I3 Laboratory - UPMC/INSERM UMRS959, France
Vaccine-induced CD8+ T Cell Immunity Strongly Predicts Lower HIV Infection Risk in HVTN 505
Holly Janes
Fred Hutchinson Cancer Research Center, United States
Induction of Unique Subset of Follicular Homing SIV-specific CD8 T Cells by Vaccination Is Associated with Enhanced Control of Pathogenic SIV
Rama Amara
Emory University, United States
Restoration of Defective T Cell Priming and Polarization in BLT Humanized Mice through Systemic Administration of IL-12p70
Daniel Claiborne
Ragon Institute of MGH, MIT and Harvard, United States
Antiviral CD8+ T Cells Restricted by HLA Class II DRB1 Exist in HIV Infection and Exhibit Clonal Expansion
Srinika Ranasinghe
Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 18: The Great Escape: Host-Virus Transmission Dynamics
Gender Differences in Transmission of HIV-1 Viral Variants and Their Impact on Early Immune Activation
Elina El-Badry
Emory University, United States
Infant Peripartum Transmitted-founder HIV-1 Variants are Resistant to Autologous Maternal Plasma Neutralization
Amit Kumar
Duke Human Vaccine Institute, United States
Transmission of Multiple HIV-1 Founder Viruses and High Frequency of Unique Recombinant Forms among MSM in Kenya
Gladys Macharia
Kenya Medical Research Institute
Higher HIV-1 Envelope Sequence Diversity in the Vaginal Tract than in Blood at Early Stage of Infection
Katja Klein
University of Western Ontario, Canada
CD8+ T Cell Dynamics in Untreated and Treated Hyperacute HIV Infection; Implications for HIV Vaccines and Cure Strategies
Zaza Ndhlovu
University of KwaZulu Natal, South Africa
Localization of the First Infected Cells after Oral Viral Exposure in Infant Maqcues
Michael McRaven
Northwestern University, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 19: Passive Immunization: Instant Protection
Rational Design of Bispecific Antibodies Targeting HIV-1 Env to Achieve Enhanced Anti-viral Potency and Breadth
James Steinhardt
Institute for Bioscience and Biotechnology Research, United States
Partial Efficacy of a Broadly Neutralizing Antibody against Cell-associated SHIV Infection
Stephen Kent
University of Melbourne, Australia
Durable Marked Attenuation and Clearance of SHIV Infection in Infant Macaques with Human Neutralizing mAbs as Post-exposure Treatment Within 48 Hours
Ann J. Hessell
Oregon Health & Science University, Oregon National Primate Research Center, United States
Virus Fitness after Infusion with Broadly Neutralizing Antibody VRC01
Rebecca Lynch
The George Washington University, United States
Rectal and Vaginal Biopsies from Men and Women Infused Intravenously with VRC01 Show Protection in Ex Vivo HIV-1 Challenge
Rena D. Astronomo
Fred Hutchinson Cancer Research Center, United States
Variable IgG Transplacental Transfer in the Setting of Maternal HIV Infection
David R. Martinez
Duke Human Vaccine Institute, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 20: Trust But Verify: Understanding Adherence
High Levels of Adherence to a Rectal Microbicide Gel and to Oral PrEP Achieved in MTN-017
Alex Carballo-Diéguez
HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, United States
Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of an Objective Measure of Adherence in ASPIRE with Self-reports of Product Use
Barbara S. Mensch
Population Council, United States
Frequency of Partner-related Social Harms and their Impact on Adherence to the Dapivirine Vaginal Ring during the MTN020/ASPIRE HIV Prevention Trial
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, South Africa
Can Infrared Spectroscopy (IR) Coupled with Chemometrics Be Used for Objective Measure of Adherence to Microbicide Products?
Oluwatosin Adedipe
CONRAD, Eastern Virginia Medical School, United States
Novel Implementation of a Real-time Adherence Monitoring Strategy within a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial
Marla J. Husnik
Fred Hutchinson Cancer Research Center, United States
Clinical Assessment of New Objective Measures of Adherence for Four Placebo Vaginal Dosage Platforms
Terry Jacot
CONRAD, Eastern Virginia Medical School, United States
from HIV Research for Prevention 2016 on 20 October 2016 10:30-12:00
Oral Abstract Session 21: Designer Envelopes for Fashionable Responses
Characterization of Transmitted/Founder CRF01_AE Virus Envelope Trimers from the RV217-early Capture HIV Cohort Study
Neeti Ananthaswamy
The Catholic University of America, United States
Targeted Deglycosylation as a Means of Vaccine Focusing
Peter Kwong
Vaccine Research Center, United States
Composition and Antigenic Effects of Individual Glycan Sites of the HIV-1 Glycan Shield
Anna-Janina Behrens
University of Oxford, United Kingdom
Delineating the Conformational Stability of the HIV-1 Envelope Glycoprotein Trimer
Branislav Ivan
University of Zurich, Switzerland
Development of a Soluble HIV-1 Env Trimer Immunogen Stabilized in the Pre-fusion Closed State from Strain CH505
Kai Xu
Vaccine Research Center, NIAID, NIH, United States
Glycan-masking Improves the CD4bs-specificity of Antibodies Elicited by eOD-GT8 60mer
Xuejun Chen
Vaccine Research Center/NIAID/NIH, United States
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Oral Abstract Session 22: Human Vaccine Clinical Trials: Reality Check
UK HVC 003: A Phase I Clinical Trial Exploring a Strategy to Maximise HIV Antibody Responses using Subtype C DNA, MVA and GLA Adjuvanted gp140
Sarah Joseph
MRC Clinical Trials Unit at UCL, United Kingdom
DNA/MVA HIV Vaccine Producing Virus-like Particles (VLPs) Is Well-tolerated and Induces Durable Functional Antibodies (Abs) in HVTN 094
Susan Buchbinder
San Francisco Department of Public Health, United States
Delayed Boost of ALVAC®HIV and AIDSVAX® B/E gp120 Following the RV144 Regimen, Significantly Increases HIV-1 Neutralizing Antibody Responses
Lindsay Wieczorek
U.S. Military HIV Research Program, United States
Characterization of HIV-1 Envelope Antibody Responses Following ALVAC-HIV and AIDSVAX B/E Prime-boost Vaccinations with Varying Late Boosts (RV306)
Siriwat Akapirat
Armed Forces Research Institute of Medical Sciences, Thailand
Upper Respiratory Tract (URT) Administration of a Replication Competent Ad4-H5-Vtn Vaccine Induces Durable Neutralizing Antibody Responses in Humans
Jinghe Huang
National Institute of Allergy and Infectious Diseases (NIAID), NIH, United States
HIV Vaccine Trials Network (HVTN) 910: Long-term Follow-up of HIV Vaccine-induced Seropositivity (VISP) among HIV Vaccinees
John Hural
HIV Vaccine Trials Network, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, United States
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Oral Abstract Session 23: Power, Pleasure and Prevention
Happy Clients: A Model for Promoting Long Acting Reversible Contraceptives
Alexandra Hoagland
Zambia Emory HIV Research Project (ZEHRP), Zambia
The Impact of a Randomized Evaluation of a Girl's Empowerment Program on HSV-2 and HIV Acquisition among Vulnerable Adolescent Girls in Zambia
Paul C. Hewett
Population Council, United States
Effectiveness of Integrated HIV Prevention and Family Planning Services for Couples in Zambia to Prevent HIV and Unintended Pregnancy
Mubiana Inambao
Zambia Emory HIV Research Project (ZEHRP), Zambia
HIV Prevention Method Using Life Skills Education Program among In-school Adolescents in South West Nigeria
Olubunmi Fakunle
Public Health Department, Nigeria
The Influence of the Vaginal Ring on Sexual Experiences of Women in an HIV Prevention Clinical Trial
Nicole Laborde
RTI International, United States
Balancing HIV Risk with Fertility Desires and Willingness to Pay for Oral PrEP to Reduce Risks: Findings from a Discrete Choice Experiment
Sheree Schwartz
Johns Hopkins Bloomberg School of Public Health, United States
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Oral Abstract Session 24: Prevention: Think Global, Prevent Local
Evaluating the Impact of the Voluntary Medical Male Circumcision (VMMC) Program in Kenya
John Stover
Avenir Health, United States
“How I Wish This Thing Was Initiated 100 Years Ago!” Willingness to Take Daily Oral Pre-exposure Prophylaxis among Men Who Have Sex with Men in Kenya
Robinson Karuga
LVCT Health, Kenya
PrEP Uptake and Demographic Characteristics of PrEP Users in Two Large Medical Systems in San Francisco
Susan Scheer
San Francisco Department of Public Health, United States
Prepping 4 Love: Engaging Focus Communities in the Development of a Citywide Social Marketing Campaign
Amy Johnson
AIDS Foundation of Chicago, United States
Studies in Orange Farm, a Township of South Africa, Revealed That Obtaining a Male Circumcision Prevalence Rate of 80% Is Difficult but Feasible
Bertran Auvert
INSERM U1018, France
Feasibility of Conducting HIV-combination Intervention Effectiveness Trials in Fishing Communities in Uganda: A Cluster Randomized Pilot
Monica Kuteesa
MRC/UVRI Uganda Research Unit on AIDS, Uganda
from HIV Research for Prevention 2016 on 20 October 2016 13:00-14:30
Oral Abstract Session 01: B Cell Immunogen Design
Structure-based Design of Trimeric V1V2 Antigens
Jason Gorman
NIH/NIAID/VRC, Bethesda, MD, United States
A Native Linked Soluble Trimer of the HIV-1 Spike Displaying Antigenic and Structural Mimetic Properties
Richard Wyatt
IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, CA, United States
A Recombinant HIV Envelope Trimer Selects for Quaternary Dependent Antibodies Targeting the Trimer Apex
Devin Sok
Scripps Research Institute, La Jolla, CA, United States
An Efficiently Cleaved HIV-1 Subtype C Env that Is Selectively Recognized by Neutralizing Antibodies: A Platform for Immunogen Design
Saikat Boliar
Translational Health Science and Technology Institute, Gurgaon, India
Minimizing Undesirable Epitope Immunodominance on HIV-1 Env Immunogens through Rational Immunogen Modification
Andrew McGuire
Seattle Biomed, Seattle, WA, United States
Uncleaved Soluble gp140 Constructs with Retained Native-like Trimer Conformation and Antigenicity
M. Gordon Joyce
National Institutes of Health, Bethesda, MD, United States
from HIV Research for Prevention 2014 on 28 October 2014 11:00-12:30
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 25 of 54